William E Klunk Selected Research

Monoclonal Antibodies

1/2023	Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease.
2/2012	Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.
4/2010	11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William E Klunk Research Topics

Disease

123	Alzheimer Disease (Alzheimer's Disease) 03/2024 - 01/2002
40	Cognitive Dysfunction 01/2024 - 03/2006
38	Dementia (Dementias) 02/2024 - 01/2008
25	Down Syndrome (Down's Syndrome) 08/2023 - 11/2012
23	Amyloid Plaque 01/2020 - 02/2002
12	Atrophy 12/2023 - 08/2005
6	Amyloidosis 02/2024 - 12/2011
6	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 02/2024 - 03/2007
5	Psychotic Disorders (Schizoaffective Disorder) 08/2015 - 01/2002
4	Neuroinflammatory Diseases 01/2023 - 01/2009
4	Tauopathies 01/2020 - 11/2015
3	Disease Progression 01/2023 - 11/2010
3	Inflammation (Inflammations) 01/2023 - 02/2012
3	Neurobehavioral Manifestations 01/2020 - 01/2016
2	Gliosis 11/2022 - 01/2021
2	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2021 - 11/2015
2	Trisomy (Trisomies) 01/2021 - 11/2012
2	Heart Diseases (Heart Disease) 01/2021 - 09/2013
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2017 - 12/2016
2	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 11/2015 - 01/2008
2	Corticobasal Degeneration 11/2015 - 09/2013
2	Frontotemporal Dementia (Semantic Dementia) 05/2015 - 01/2008
1	Craniocerebral Trauma (Head Injury) 11/2023
1	Substance-Related Disorders (Drug Abuse) 11/2023
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2023
1	Clinical Deterioration 01/2023
1	Cerebral Cortical Thinning 01/2022
1	Vascular Diseases (Vascular Disease) 09/2021
1	Hippocampal Sclerosis 01/2020
1	Genetic Predisposition to Disease (Genetic Predisposition) 04/2019
1	Prodromal Symptoms 01/2019
1	Death (Near-Death Experience) 12/2016
1	Multiple System Atrophy 11/2015
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 09/2015
1	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 05/2015
1	Pathologic Processes 12/2014
1	Amyloid angiopathy 01/2014
1	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2014
1	Parkinson Disease (Parkinson's Disease) 10/2013
1	Diabetes Mellitus 09/2013
1	Stroke (Strokes) 09/2013
1	Hypertension (High Blood Pressure) 09/2013

Drug/Important Bio-Agent (IBA)

115	Amyloid (Amyloid Fibrils)IBA 02/2024 - 02/2002
40	Biomarkers (Surrogate Marker)IBA 03/2024 - 10/2003
35	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 01/2023 - 06/2003
25	Amyloid beta-PeptidesIBA 12/2023 - 11/2002
12	Apolipoproteins E (ApoE)IBA 01/2023 - 01/2002
11	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2005
7	ApolipoproteinsIBA 10/2023 - 01/2002
7	LigandsIBA 01/2017 - 07/2004
4	Peptides (Polypeptides)IBA 01/2019 - 06/2008
4	CarbonIBA 04/2016 - 10/2007
3	Monoclonal AntibodiesIBA 01/2023 - 04/2010
3	tau Proteins (tau Protein)IBA 01/2023 - 08/2012
3	Coloring Agents (Dyes)IBA 01/2021 - 11/2012
3	flutemetamolIBA 10/2020 - 01/2015
3	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2006
2	Presenilin-1IBA 02/2024 - 11/2005
2	Antihypertensive Agents (Antihypertensives)IBA 01/2021 - 01/2018
2	Synaptosomal-Associated Protein 25IBA 01/2021 - 01/2020
2	thioflavin TIBA 01/2021 - 10/2007
2	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA 01/2021 - 01/2017
2	NeurocalcinIBA 01/2021 - 01/2020
2	Chitinase-3-Like Protein 1IBA 01/2021 - 01/2020
2	alpha-SynucleinIBA 01/2020 - 10/2013
2	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2020 - 11/2015
2	bapineuzumabIBA 08/2015 - 04/2010
1	Protease Inhibitors (Protease Inhibitor)IBA 03/2024
1	Peptide Hydrolases (Proteases)FDA Link 03/2024
1	Codon (Codons)IBA 02/2024
1	AminesIBA 01/2023
1	Messenger RNA (mRNA)IBA 01/2023
1	antineoplaston A10 (A 10)IBA 01/2022
1	splenotritin (TP3)IBA 01/2022
1	Threonine (L-Threonine)FDA Link 01/2021
1	NeurograninIBA 01/2020
1	Nerve Growth Factors (Neurotrophins)IBA 01/2019
1	Becaplermin (PDGF-BB)FDA Link 01/2019
1	CytokinesIBA 01/2019
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2018
1	DiureticsIBA 01/2018
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2018
1	TenascinIBA 01/2016
1	Glycoproteins (Glycoprotein)IBA 01/2016
1	SynucleinsIBA 11/2015
1	EmulsionsIBA 11/2015
1	pentamer formyl thiophene acetic acidIBA 07/2015
1	CholesterolIBA 04/2014
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 03/2014
1	TritiumIBA 01/2014
1	Contrast MediaIBA 10/2013
1	Antipsychotic Agents (Antipsychotics)IBA 09/2013
1	RheniumIBA 03/2013
1	PresenilinsIBA 11/2012

Therapy/Procedure

11	Therapeutics 01/2020 - 09/2002
1	Contraindications 11/2023
1	Immunotherapy 01/2021
1	Secondary Prevention 08/2015
1	Institutionalization (Institutionalized Persons) 09/2013
1	Home Nursing (Nursing, Home) 09/2013